Sunitinib and the benefits of a negative study

The Lancet Oncology

Volumn 10, Issue 8, 2009, Pages 743-744

  Forner, Alejandro ^a   Llovet, Josep M ^a,b   Bruix, Jordi ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB;

ANTINEOPLASTIC ACTIVITY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG RESPONSE; DRUG SAFETY; HUMAN; IC 50; LETTER; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DYSFUNCTION; PATIENT SELECTION; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS AS TOPIC; HUMANS; INDOLES; LIVER NEOPLASMS; PYRROLES;

EID: 67749089441     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(09)70206-2     Document Type: Letter

References (5)

1. Llovet J.M., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359 (2008) 378-390
2. Llovet J.M., and Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48 (2008) 1312-1327
3. Llovet J.M., Di Bisceglie A.M., Bruix J., et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100 (2008) 698-711
4. Faivre S., Raymond E., Boucher E., et al. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: a phase II study. Lancet Oncol 10 (2009) 794-800
5. Zhu A.X., Sahani D.V., Duda D.G., et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 27 (2009) 3027-3035